An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2014
At a glance
- Drugs Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms PEGIMPACT
- Sponsors Merck & Co; Schering-Plough
- 03 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 12 Nov 2008 Planned initiation date changed from 1 Sep 2008 to 1 Jan 2009.
- 21 Jul 2008 New trial record.